Dario Uniquely Positioned to Amplify the Impact of Oral GLP-1 Therapies Through Precision Behavioral Support: 79% of Members Already Using Dario's Weight Management
MWN-AI** Summary
DarioHealth Corp. (NASDAQ: DRIO), a leader in digital health solutions, is strategically positioned to enhance the effectiveness of oral GLP-1 therapies through its innovative precision behavioral support. As oral GLP-1 medications are introduced, they are anticipated to yield slightly lower weight loss and glycemic control than their injectable counterparts, making the support structures around their use vital for success. Dario's data indicates that an impressive 79% of its members actively engage in weight management, leveraging the company’s integrated multi-condition platform, which harnesses behavioral reinforcement to improve real-world outcomes.
With the burgeoning costs associated with GLP-1 medications—one of the fastest-growing medical expenses for payers—Dario's approach aims to not only drive patient adherence but also achieve better long-term health outcomes while reducing expenses for employers and health plans. Dario's solutions include a medication cabinet for adherence tracking, a grocery scanner for informed food choices, and access to personal coaching, creating a robust behavioral infrastructure that fosters sustainable changes in lifestyle and health.
Dario's Chief Commercial Officer, Steven Nelson, emphasizes that pharmacotherapy must be complemented with behavioral support to maximize healthcare investments, especially as the market for oral GLP-1s is projected to expand significantly, capturing around 25% of the GLP-1 market by 2030. The potential for improved outcomes through structured support is critical, according to Dario's Chief Medical Officer, Dr. Omar Manejwala, highlighting the need for daily behavioral reinforcement as oral therapies gain traction.
Dario’s unique digital health platform revolutionizes chronic condition management, enabling comprehensive care and facilitating sustained behavior change for its users, ultimately driving exceptional satisfaction and retention.
MWN-AI** Analysis
DarioHealth Corp. (NASDAQ: DRIO) is strategically positioned to leverage the increasing demand for oral GLP-1 therapies by integrating precision behavioral support into its digital health solutions. With 79% of members currently utilizing Dario's weight management platform, the company holds a competitive advantage in enhancing medication adherence and efficacy in a rapidly evolving market.
As the landscape shifts towards oral GLP-1 medications—expected to encompass 25% of the $95 billion GLP-1 market by 2030—Dario’s emphasis on daily behavioral reinforcement becomes crucial. The effectiveness of these therapies hinges on patient engagement and consistent behavioral habits, areas where Dario excels through its user-centric design and personalized coaching. This is particularly important considering that oral formulations tend to offer more modest results compared to their injectable counterparts.
Investors should view Dario as a crucial player in addressing one of the fastest-growing expenses for payers—GLP-1 medication costs—by proposing solutions aimed at optimizing long-term health outcomes and reducing overall spending. As the demand from employers and health plans escalates, Dario’s unique offerings can deliver higher ROI by facilitating sustained patient engagement.
For potential investors, the ability to reduce premature discontinuation and improve patient experiences positions Dario favorably within the healthcare ecosystem. The rollout of innovative tools like medication adherence tracking and personalized coaching further fortify its market stance.
Thus, it may be prudent to consider investing in DarioHealth as it navigates the growing adoption of oral GLP-1 therapies. The combination of a deep understanding of patient needs, a robust digital platform, and an increasing focus on behavioral support could lead to enhanced outcomes, making it a worthy candidate for portfolio diversification within the healthcare sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
As oral GLP-1s enter the market with slightly more modest weight and glycemic outcomes than injectable formulations, Dario integrates structured behavioral reinforcement to optimize real-world success
Given GLP-1 medication expense is one of the fastest-growing cost drivers for payers, Dario enables real-world patient adherence to deliver better long term health outcomes and reduced spending for clients resulting in higher ROI
NEW YORK, March 3, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced increasing employer and health plan demand for its oral GLP-1 digital health solution, which is purpose-built to strengthen medication impact through precision behavioral support at scale.
As oral GLP-1 therapies enter the market, data suggest they deliver slightly more modest weight and glycemic outcomes compared to injectable formulations. That dynamic elevates the importance of the surrounding behavioral infrastructure. Success ultimately depends on daily execution – timing, fasting windows, food decisions, symptom management and persistence through adjustment periods.
Dario's book of business data shows that 79% of members engage in weight management within its integrated multi-condition platform. As a result, the Company has an extensive population benefiting from the solution's structured reinforcement.
Dario's deep experience and data around weight management is a critical asset, as GLP-1 medication spending remains one of the fastest-growing cost drivers for payers – with oral GLP-1s expected to capture 25% of the overall GLP-1 market, projected to reach $95 billion by 2030, according to Goldman Sachs.
"Oral GLP-1 access is expanding rapidly," said Steven Nelson, Chief Commercial Officer and President of Dario. "But pharmacotherapy without behavioral infrastructure leaves outcomes on the table. Dario's solutions are designed to amplify impact – helping employers and health plans maximize return on their GLP-1 investment through precision support that translates intention into sustained action."
Rather than layering generic education around therapy, Dario embeds precision behavioral tools directly into the treatment journey. Key capabilities include:
- Medication cabinet to support adherence tracking and reduce dose-timing drift
- Grocery scanner to translate weight-loss intent into smarter real-world food decisions
- Access to a personal human coach to reinforce habit formation and persistence
Together, these features create a tightly paired intervention model – aligning pharmacotherapy with real-time awareness to reinforce sustained behavior change.
"Oral GLP-1s may require stronger behavioral reinforcement to optimize outcomes," said Dr. Omar Manejwala, Chief Medical Officer at Dario. "Dario was created to drive daily behaviors – not just educate about them – and that distinction becomes even more critical with oral formulations."
As the use of oral GLP1's expands beyond specialty care into primary care and employer populations, scale introduces new challenges in monitoring adherence, managing early side effects and preventing premature discontinuation. Without structured behavioral support, modest efficacy combined with inconsistent habits can erode long-term value.
About DarioHealth Corp. (NASDAQ: DRIO)
DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected growth and adoption of oral GLP-1 therapies; the projected expansion of employer and health plan demand; the anticipated ability of the Company's platform to improve adherence; the potential to optimize weight and glycemic outcomes; the expectation that behavioral support will enhance medication impact; the projected market size and penetration of oral GLP-1s; the anticipated return on investment for payers and employers; the expected long-term health and cost outcomes; the belief that the Company's solution is uniquely positioned in the market; and the anticipated scalability of the platform across care settings. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contacts
Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310
Rob Halpern
SVP Marketing
irteam@dariohealth.com
Logo - https://mma.prnewswire.com/media/2866807/Dario_Logo.jpg
SOURCE DarioHealth Corp.
FAQ**
How does DarioHealth Corp. (NASDAQ: DRIO) plan to leverage its data on weight management to enhance the effectiveness of oral GLP-1 therapies and ensure better long-term health outcomes for members?
With 79% of members engaging in weight management, what unique behavioral strategies does DarioHealth Corp. (NASDAQ: DRIO) deploy to improve adherence to oral GLP-1 therapies among its users?
Considering the projected market for oral GLP-1s to reach $95 billion by 2030, how does DarioHealth Corp. (NASDAQ: DRIO) anticipate capturing market share while addressing the growing demand for integrated digital health solutions?
Can DarioHealth Corp. (NASDAQ: DRIO) share specific outcomes or metrics that demonstrate the ROI for employers and health plans leveraging their platform to optimize medication adherence for oral GLP-1 therapies?
**MWN-AI FAQ is based on asking OpenAI questions about DarioHealth Corp. (NASDAQ: DRIO).
NASDAQ: DRIO
DRIO Trading
5.48% G/L:
$9.82 Last:
2,939 Volume:
$9.38 Open:
